Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00332137
Status:
COMPLETED
Last Update Posted:
2011-03-23
First Post:
2006-05-30
Brief Title:
Effects of Tolterodine a Non-Specific Muscarinic Antagonist on Gastrointestinal Transit in Healthy Subjects
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Effects of Tolterodine a Non-Specific Muscarinic Antagonist on Gastrointestinal Transit in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The muscarinic antagonist tolterodine is widely used treat urinary urge incontinence Though acteylcholine is the primary excitatory neurotransmitter in the gastrointestinal tract the phase III trials suggest that tolterodine infrequently causes constipation Therefore the objectives of this study are to assess if tolterodine affects the speed at which food travels through the stomach intestines and colon ie gastrointestinal and colonic transit in healthy subjects
Detailed Description:
The specific aims of this study are to test the hypotheses that the non-specific muscarinic antagonist tolterodine will not- i delay colonic transit and the proximal colonic emptying rate ii delay gastric emptying nor iii delay small intestinal transit compared to placebo in healthy subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None